Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells. (June 2018)

Record Type:: Journal Article
Title:: Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells. (June 2018)
Main Title:: Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells
Authors:: Tsujikawa, Laura
Kulikowski, Ewelina
Calosing, Cyrus
Wasiak, Sylwia
Gilham, Dean
Halliday, Christopher
Johansson, Jan
Sweeney, Mike
Wong, Norm
Abstract:
Is Part Of:: Atherosclerosis. Volume 32(2018)
Journal:: Atherosclerosis
Issue:: Volume 32(2018)
Issue Display:: Volume 32, Issue 2018 (2018)
Year:: 2018
Volume:: 32
Issue:: 2018
Issue Sort Value:: 2018-0032-2018-0000
Page Start:: 104
Page End:
Publication Date:: 2018-06
Subjects:: Atherosclerosis -- Periodicals
Cardiovascular system -- Diseases -- Periodicals
Periodicals
616.136
Journal URLs:: http://www.sciencedirect.com/science/journal/15675688 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/j.atherosclerosissup.2018.04.318 ↗
Languages:: English
ISSNs:: 1567-5688
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1765.875000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 6758.xml